Related Experiment Video
Updated: May 12, 2026

Three-Dimensional Culture of Murine Colonic Crypts to Study Intestinal Stem Cell Function Ex Vivo
Published on: October 11, 2022
Overexpression of claudin-4 may be involved in endometrial tumorigenesis
Xiao-Yu Pan1, Xue Li, Yan-Ci Che
1Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing 100029;
Abstract:
To clarify the role of claudin-4 in endometrial tumorigenesis and to explore whether claudin-4 could be a potentially useful agent in the treatment of endometrial carcinoma, the expression of claudin-4 in endometrial carcinoma was investigated. The relationship between therapy with anti-neoplastic agents and the expression of claudin-4 was also analyzed using an endometrial carcinoma xenograft model. The expression of claudin-4 in endometrial endometrioid adenocarcinoma (EEC) and normal human endometrial tissue was determined using immunohistochemistry and real-time PCR. Ninety female BALB/c nu/nu mice were transplanted with Ishikawa endometrial cancer cells. The mice were divided into three groups with different intraperitoneal treatments: cisplatin, paclitaxel or saline solution. After the observation period tumors were extracted and stained with monoclonal antibody against claudin-4. The mRNA expression of claudin-4 was also detected using real-time PCR. Expression of claudin-4 was significantly increased at both protein and mRNA levels in the EEC group compared with the group of normal cyclic endometrium. In the study of Ishikawa xenografts, no significant changes in tumor volume and claudin-4 expression were shown in the paclitaxel group compared with the control group. A significant reduction of tumor growth and a significant decrease in claudin-4 expression were observed in the cisplatin group. These results demonstrate that claudin-4 is strongly expressed in EEC. Claudin-4 is a useful biomarker in the treatment of patients with endometrial carcinoma.
Insights
Claudin-4 expression is elevated in endometrial endometrioid adenocarcinoma (EEC). Cisplatin treatment reduced tumor growth and claudin-4 levels, suggesting claudin-4 is a potential biomarker for endometrial cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Claudin-4 plays a role in epithelial cell adhesion and barrier function.
- Its role in endometrial tumorigenesis and potential as a therapeutic target remains to be fully elucidated.
Purpose of the Study:
- To investigate the expression of claudin-4 in endometrial carcinoma.
- To explore claudin-4 as a potential therapeutic agent and biomarker in endometrial carcinoma treatment.
Main Methods:
- Immunohistochemistry and real-time PCR were used to assess claudin-4 expression in endometrial endometrioid adenocarcinoma (EEC) and normal endometrial tissue.
- An endometrial carcinoma xenograft model (Ishikawa cells in mice) was used to evaluate the effect of cisplatin and paclitaxel on tumor growth and claudin-4 expression.
Main Results:
- Claudin-4 expression was significantly increased at both protein and mRNA levels in EEC compared to normal endometrium.
- Paclitaxel treatment did not significantly alter tumor volume or claudin-4 expression.
- Cisplatin treatment led to a significant reduction in tumor growth and a significant decrease in claudin-4 expression.
Conclusions:
- Claudin-4 is highly expressed in endometrial endometrioid adenocarcinoma.
- Claudin-4 may serve as a valuable biomarker for predicting response to cisplatin treatment in endometrial carcinoma.
Related Concept Videos
Oogenesis
Cellular Adaptation IV: Dysplasia and Metaplasia
Abnormal Proliferation
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Disorders of the Female Reproductive System
